AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$NOVT

Secor Thomas N sold $98K of NOVT

Secor Thomas N sold 663 shares of NOVANTA INC (NOVT) at $147.60 on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Secor Thomas N
Published Sep 15, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NOVT
Neutral
high confidence
Mentioned
$NOVT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NOVTNeutralLow
01

Why it matters

The sale is modest and does not suggest a material change in insider confidence.

02

Market read

Limited relevance; primarily of interest to investors tracking insider activity.

03

What to watch

Potential upcoming corporate actions or earnings that may affect insider holdings.

Relevance 2/10Novelty 4/10Timing: filed after market close on 2026-09-15

Background

SEC Form 4 filing discloses insider transactions; required for directors and officers.

Company-level read

Ticker impact

$NOVTNeutralHigh confidence
Context

Director Thomas N. Secor sold 663 shares of NOVANTA for $97,858, reducing his stake to 662 shares.

Expected impact

No significant impact expected.

Evidence & confidence

The transaction size (~$98K) is small relative to market cap and typical trading volume.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

If the director's sale signals concerns, a short position could be considered, but evidence is weak.

Key entities

  • Company
    Novanta Inc.

    Medical device and technology company listed on NYSE.

  • Individual
    Thomas N. Secor

    Director of Novanta Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NOVT insider trading history →

Related articles

SEP 4
$NOVTMedAI 8/10

Novanta’s (NOVT) Second Quarter Shows Profits Outrunning Sales

Novanta Inc. (NOVT) reported Q2 revenue of $265.8M, up 10.3% YoY, with net income nearly tripling and cash from operations quadrupling. Adjusted EBITDA rose 16.4% to $60.7M. The company acquired Riverpoint Medical, expanding its medical consumables business. Q3 guidance projects over 21% revenue growth. Hedge fund ownership increased, but short interest remains high at 14.58% of float.

insidermonkey.com2 min
SEP 2
$AEISMed

Electronic Components Stocks Q2 Results: Benchmarking Advanced Energy (NASDAQ:AEIS)

Eight electronic components stocks reported Q2 revenues 3.3% above estimates, with next quarter's guidance 6.9% higher. Despite strong results, shares fell 7.2% on average. Advanced Energy (AEIS) saw $574.1M revenue (up 30% YoY, 5.6% beat), but its stock dropped 10%. Allient (ALNT) and Littelfuse (LFUS) also beat estimates, while nLIGHT (LASR) missed EBITDA guidance, falling 46.4%.

tradingview.com3 min
AUG 13
$NOVTMedAI 9/10

Novanta (NOVT) Q2 2026 Earnings Call Transcript

Novanta Inc. (NOVT) reported Q2 2026 revenue of $265.8 million, up 10.3% (9.3% organic). Adjusted EPS was $0.89, up 17.1%, with adjusted EBITDA of $60.7 million. The company raised 2026 guidance for revenue ($1.13B-$1.14B) and adjusted EBITDA ($273M-$278M) after completing the Riverpoint Medical acquisition, expected to add ~$65M revenue and ~$25M adjusted EBITDA in 2H26.

fool.com6 min
AUG 5
$NOVTHighAI 9/10

Novanta Announces Financial Results for the Second Quarter 2026

Novanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.

leaderpost.com6 min
AUG 5
$NOVTHigh

NOVANTA INC (NOVT): Results of Operations and Financial Condition

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and Adjusted EBITDA increased 16% to $61 milli

SEC EDGAR 8-K6 min